Active Ingredient History
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors. Eplerenone binds to the mineralocorticoid receptor and thereby blocks the binding of aldosterone (component of the renin-angiotensin-aldosterone-system, or RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms. Used for improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aortic Aneurysm, Abdominal (Phase 4)
Aortic Stenosis, Subvalvular (Early Phase 1)
Arterial Switch Operation (Phase 4)
Arteries (Phase 4)
Ascites (Phase 2)
Atrial Fibrillation (Phase 4)
Breast Neoplasms (Phase 2/Phase 3)
Cardiomyopathies (Phase 4)
Central Serous Chorioretinopathy (Phase 4)
Chronic Kidney Disease-Mineral and Bone Disorder (Phase 1/Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 2)
Dialysis (Phase 4)
Diastole (Phase 4)
Endothelial Cells (Phase 3)
Essential Hypertension (Phase 4)
Fasting (Phase 1)
Fibrosis (Phase 2)
Glucose Intolerance (Phase 3)
Healthy Volunteers (Phase 1)
Heart Failure, Diastolic (Phase 4)
Heart Failure, Systolic (Phase 4)
Heart Ventricles (Phase 4)
Hyperaldosteronism (Phase 4)
Hyperparathyroidism, Primary (Phase 2/Phase 3)
Hypertension ()
Hypertrophy, Left Ventricular (Phase 4)
Insulin Resistance (Phase 4)
Intervertebral Disc Degeneration (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 3)
Low Back Pain (Phase 4)
Metabolic Syndrome (Phase 4)
Minerals (Phase 4)
MINOCA (Phase 2)
Muscular Dystrophy, Duchenne (Phase 3)
Mutation (Phase 3)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 4)
Myocardium (Phase 2)
Obesity (Phase 4)
Pharmacokinetics (Phase 4)
Pharmacology, Clinical (Phase 1)
Proteinuria (Phase 4)
Quality of Life (Early Phase 1)
Renal Insufficiency, Chronic (Phase 4)
Retinal Diseases (Phase 2)
Sciatic Neuropathy (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Steatitis (Phase 2)
Tetralogy of Fallot (Phase 4)
Therapeutic Equivalency (Phase 1)
Transposition of Great Vessels (Phase 4)
Ventricular Dysfunction, Left (Phase 4)
Vitreous Body (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
